Sera of patients infected by earlier lineages of SARS-CoV-2 are capable to neutralize later emerged variants of concern

Detalhes bibliográficos
Autor(a) principal: Pauvolid-Corrêa, Alex
Data de Publicação: 2022
Outros Autores: Caetano, Braulia Costa, Machado, Ana Beatriz, Ferreira, Mia Araújo, Valente, Natalia, Neves, Thayssa Keren, Geraldo, Kim, Motta, Fernando, Veloso, Valdiléa G., Grinsztejn, Beatriz, Siqueira, Marilda Mendonça, Resende, Paola Cristina
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da FIOCRUZ (ARCA)
Texto Completo: https://www.arca.fiocruz.br/handle/icict/56780
Resumo: Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Referência COVID-19 da Organização Mundial da Saúde e Laboratório Nacional de Referência COVID-19 do Brasil. Laboratório de Vírus Respiratórios e Sarampo. Rio de Janeiro, RJ, Brasil / Texas A&M University. Department of Veterinary Integrative Biosciences. College Station, TX, USA / Universidade Federal de Viçosa. Departamento de Veterinária. Viçosa, MG, Brasil.
id CRUZ_907eaa2a913c9cf3bd533e4ac6da2720
oai_identifier_str oai:www.arca.fiocruz.br:icict/56780
network_acronym_str CRUZ
network_name_str Repositório Institucional da FIOCRUZ (ARCA)
repository_id_str 2135
spelling Pauvolid-Corrêa, AlexCaetano, Braulia CostaMachado, Ana BeatrizFerreira, Mia AraújoValente, NataliaNeves, Thayssa KerenGeraldo, KimMotta, FernandoVeloso, Valdiléa G.Grinsztejn, BeatrizSiqueira, Marilda MendonçaResende, Paola Cristina2023-01-31T10:20:19Z2023-01-31T10:20:19Z2022PAUVOLID-CORRÊA, Alex et al. Sera of patients infected by earlier lineages of SARS-CoV-2 are capable to neutralize later emerged variants of concern. Biology Methods & Protocols, v. 7, n. 1, p. 1-6, 2022.2396-8923https://www.arca.fiocruz.br/handle/icict/5678010.1093/biomethods/bpac021engOxfordSera of patients infected by earlier lineages of SARS-CoV-2 are capable to neutralize later emerged variants of concerninfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleFundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Referência COVID-19 da Organização Mundial da Saúde e Laboratório Nacional de Referência COVID-19 do Brasil. Laboratório de Vírus Respiratórios e Sarampo. Rio de Janeiro, RJ, Brasil / Texas A&M University. Department of Veterinary Integrative Biosciences. College Station, TX, USA / Universidade Federal de Viçosa. Departamento de Veterinária. Viçosa, MG, Brasil.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Referência COVID-19 da Organização Mundial da Saúde e Laboratório Nacional de Referência COVID-19 do Brasil. Laboratório de Vírus Respiratórios e Sarampo. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Referência COVID-19 da Organização Mundial da Saúde e Laboratório Nacional de Referência COVID-19 do Brasil. Laboratório de Vírus Respiratórios e Sarampo. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Referência COVID-19 da Organização Mundial da Saúde e Laboratório Nacional de Referência COVID-19 do Brasil. Laboratório de Vírus Respiratórios e Sarampo. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Referência COVID-19 da Organização Mundial da Saúde e Laboratório Nacional de Referência COVID-19 do Brasil. Laboratório de Vírus Respiratórios e Sarampo. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Referência COVID-19 da Organização Mundial da Saúde e Laboratório Nacional de Referência COVID-19 do Brasil. Laboratório de Vírus Respiratórios e Sarampo. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Referência COVID-19 da Organização Mundial da Saúde e Laboratório Nacional de Referência COVID-19 do Brasil. Laboratório de Vírus Respiratórios e Sarampo. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Referência COVID-19 da Organização Mundial da Saúde e Laboratório Nacional de Referência COVID-19 do Brasil. Laboratório de Vírus Respiratórios e Sarampo. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Referência COVID-19 da Organização Mundial da Saúde e Laboratório Nacional de Referência COVID-19 do Brasil. Laboratório de Vírus Respiratórios e Sarampo. Rio de Janeiro, RJ, Brasil.Serum samples of 20 hospitalized coronavirus disease 2019 (COVID-19) patients from Brazil who were infected by the earlier severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lineages B.1.1.28 and B.1.1.33, and by the variant of concern (VOC) Gamma (P.1) were tested by plaque reduction neutralization test (PRNT90) with wild isolates of a panel of SARS-CoV-2 lineages, including B.1, Zeta, N.10, and the VOCs Gamma, Alpha, and Delta that emerged in different timeframes of the pandemic. The main objective of this study was to evaluate if the serum of patients infected by earlier lineages was capable to neutralize later emerged VOCs. We also evaluated if the 4-fold difference in PRNT90 titers is a reliable seropositivity criterion to distinguish infections caused by different SARS-CoV-2 lineages. Sera collected between May 2020 and August 2021 from the day of admittance to the hospital to 21 days after diagnostic of patients infected by the two earlier lineages B.1.1.28 and B.1.1.33 presented neutralizing capacity for all challenged VOCs, including Gamma and Delta. Among all variants tested, Delta and N.10 presented the lowest geometric mean of neutralizing antibody titers, and B.1.1.7, presented the highest titers. Four patients infected with Gamma, that emerged in December 2020, presented neutralizing antibodies for B.1, B.1.1.33, and B.1.1.28, its ancestor lineage. All of them had neutralizing antibodies under the level of detection for the VOC Delta. Patients infected by B.1.1.28 presented very similar geometric mean of neutralizing antibody titers for both B.1.1.33 and B.1.1.28. Findings presented here indicate that most patients infected in early stages of COVID-19 pandemic presented neutralizing antibodies capable to neutralize wild types of all later emerged VOCs in Brazil, and that the 4-fold difference in PRNT90 titers is not reliable to distinguish humoral response among different SARS-CoV-2 lineages.BrazilPRNTSARS-CoV-2HumoralImmuneVariantsCOVID-19info:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZORIGINALSera_Beatriz_Grinsztejn_etal_INI_2022_COVID-19.pdfSera_Beatriz_Grinsztejn_etal_INI_2022_COVID-19.pdfapplication/pdf400834https://www.arca.fiocruz.br/bitstream/icict/56780/2/Sera_Beatriz_Grinsztejn_etal_INI_2022_COVID-19.pdf119d26f0bbab3cabc61f2d7424a1e49bMD52LICENSElicense.txtlicense.txttext/plain; charset=utf-82991https://www.arca.fiocruz.br/bitstream/icict/56780/1/license.txt5a560609d32a3863062d77ff32785d58MD51icict/567802023-09-04 11:17:45.049oai:www.arca.fiocruz.br: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ório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352023-09-04T14:17:45Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false
dc.title.en_US.fl_str_mv Sera of patients infected by earlier lineages of SARS-CoV-2 are capable to neutralize later emerged variants of concern
title Sera of patients infected by earlier lineages of SARS-CoV-2 are capable to neutralize later emerged variants of concern
spellingShingle Sera of patients infected by earlier lineages of SARS-CoV-2 are capable to neutralize later emerged variants of concern
Pauvolid-Corrêa, Alex
Brazil
PRNT
SARS-CoV-2
Humoral
Immune
Variants
COVID-19
title_short Sera of patients infected by earlier lineages of SARS-CoV-2 are capable to neutralize later emerged variants of concern
title_full Sera of patients infected by earlier lineages of SARS-CoV-2 are capable to neutralize later emerged variants of concern
title_fullStr Sera of patients infected by earlier lineages of SARS-CoV-2 are capable to neutralize later emerged variants of concern
title_full_unstemmed Sera of patients infected by earlier lineages of SARS-CoV-2 are capable to neutralize later emerged variants of concern
title_sort Sera of patients infected by earlier lineages of SARS-CoV-2 are capable to neutralize later emerged variants of concern
author Pauvolid-Corrêa, Alex
author_facet Pauvolid-Corrêa, Alex
Caetano, Braulia Costa
Machado, Ana Beatriz
Ferreira, Mia Araújo
Valente, Natalia
Neves, Thayssa Keren
Geraldo, Kim
Motta, Fernando
Veloso, Valdiléa G.
Grinsztejn, Beatriz
Siqueira, Marilda Mendonça
Resende, Paola Cristina
author_role author
author2 Caetano, Braulia Costa
Machado, Ana Beatriz
Ferreira, Mia Araújo
Valente, Natalia
Neves, Thayssa Keren
Geraldo, Kim
Motta, Fernando
Veloso, Valdiléa G.
Grinsztejn, Beatriz
Siqueira, Marilda Mendonça
Resende, Paola Cristina
author2_role author
author
author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Pauvolid-Corrêa, Alex
Caetano, Braulia Costa
Machado, Ana Beatriz
Ferreira, Mia Araújo
Valente, Natalia
Neves, Thayssa Keren
Geraldo, Kim
Motta, Fernando
Veloso, Valdiléa G.
Grinsztejn, Beatriz
Siqueira, Marilda Mendonça
Resende, Paola Cristina
dc.subject.en.en_US.fl_str_mv Brazil
PRNT
SARS-CoV-2
Humoral
Immune
Variants
topic Brazil
PRNT
SARS-CoV-2
Humoral
Immune
Variants
COVID-19
dc.subject.en.none.fl_str_mv COVID-19
description Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Referência COVID-19 da Organização Mundial da Saúde e Laboratório Nacional de Referência COVID-19 do Brasil. Laboratório de Vírus Respiratórios e Sarampo. Rio de Janeiro, RJ, Brasil / Texas A&M University. Department of Veterinary Integrative Biosciences. College Station, TX, USA / Universidade Federal de Viçosa. Departamento de Veterinária. Viçosa, MG, Brasil.
publishDate 2022
dc.date.issued.fl_str_mv 2022
dc.date.accessioned.fl_str_mv 2023-01-31T10:20:19Z
dc.date.available.fl_str_mv 2023-01-31T10:20:19Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.citation.fl_str_mv PAUVOLID-CORRÊA, Alex et al. Sera of patients infected by earlier lineages of SARS-CoV-2 are capable to neutralize later emerged variants of concern. Biology Methods & Protocols, v. 7, n. 1, p. 1-6, 2022.
dc.identifier.uri.fl_str_mv https://www.arca.fiocruz.br/handle/icict/56780
dc.identifier.issn.en_US.fl_str_mv 2396-8923
dc.identifier.doi.none.fl_str_mv 10.1093/biomethods/bpac021
identifier_str_mv PAUVOLID-CORRÊA, Alex et al. Sera of patients infected by earlier lineages of SARS-CoV-2 are capable to neutralize later emerged variants of concern. Biology Methods & Protocols, v. 7, n. 1, p. 1-6, 2022.
2396-8923
10.1093/biomethods/bpac021
url https://www.arca.fiocruz.br/handle/icict/56780
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Oxford
publisher.none.fl_str_mv Oxford
dc.source.none.fl_str_mv reponame:Repositório Institucional da FIOCRUZ (ARCA)
instname:Fundação Oswaldo Cruz (FIOCRUZ)
instacron:FIOCRUZ
instname_str Fundação Oswaldo Cruz (FIOCRUZ)
instacron_str FIOCRUZ
institution FIOCRUZ
reponame_str Repositório Institucional da FIOCRUZ (ARCA)
collection Repositório Institucional da FIOCRUZ (ARCA)
bitstream.url.fl_str_mv https://www.arca.fiocruz.br/bitstream/icict/56780/2/Sera_Beatriz_Grinsztejn_etal_INI_2022_COVID-19.pdf
https://www.arca.fiocruz.br/bitstream/icict/56780/1/license.txt
bitstream.checksum.fl_str_mv 119d26f0bbab3cabc61f2d7424a1e49b
5a560609d32a3863062d77ff32785d58
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
repository.name.fl_str_mv Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)
repository.mail.fl_str_mv repositorio.arca@fiocruz.br
_version_ 1813008987156643840

Registros relacionados